Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35404669.
- Also identified by DOI 10.7326/M22-1026 and PMC identifier 9026000.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
On 8 December 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZeneca's Evusheld (tixagevimab copackaged with cilgavimab, administered as concomitant injections) for the prevention of COVID-19 in those who are moderately to severely compromised, are aged 12 years or older, and weigh more than 40 kg. This commentary discusses current appropriate use of this important preventive intervention.
Medical subject headings
- COVID-19
- Vaccines